CancerWorld/Linkedin
Jul 30, 2025, 08:52
Empowering Patients in Europe’s New HTA Framework – CancerWorld
CancerWorld shared a post on LinkedIn:
“Empowering Patients in Europe’s New HTA Framework.
Cancer patients across the EU often face long delays, even after European Medicines Agency (EMA) approval, before accessing new treatments.
The EU’s new Health Technology Assessment (HTA) Regulation, effective January 2025, aims to change that by introducing a unified evaluation process.
Key highlights:
- Joint Clinical Assessments (JCAs): Streamlining clinical evaluations at the EU level.
- Patient Involvement: Ensuring patient perspectives are integrated throughout the assessment process.
While challenges remain, this shift marks a significant step towards faster and more equitable access to life-saving therapies.
Read the full article.”
More posts featuring CancerWorld.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 18, 2025, 15:58
Aug 18, 2025, 15:02